Fig. 5

Inhibition of fibril formation of different Tau mutants in the presence of ISAD1 and ISAD1rev. For the fibrillization assay, 10 μM of each Tau mutant was diluted with 2.5 μM heparin and 20 μM ThS in BES buffer. The D-peptides ISAD1 and ISAD1rev were added to and incubated at 37 °C for 24 h. The fluorescence was measured every 30 min. The fluorescence of the respective Tau control after 24 h was set as 100%, and the values and standard deviations of the other incubations are given as percentages of this maximum value. A Inhibition of Tau^FLΔK fibrillization by ISAD1 peptides [n = 3; one-way ANOVA with Tukey’s post hoc test; F(6, 56) = 691; ***p ≤ 0.001]. B ISAD1 and ISAD1rev inhibit the fibrillization of Tau^FL-A152T [n = 3; one-way ANOVA with Tukey’s post hoc test; F(6, 56) = 2455; ***p ≤ 0.001]. C ISAD1 peptides show inhibition of Tau^FL-P301L fibrillization. Significant differences are shown with respect to the respective Tau isoform control (gray) [n = 3; one-way ANOVA with Tukey’s post hoc test; F(6, 56) = 809; ***p ≤ 0.001]